Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Work In Process (2022 - 2026)

Gyre Therapeutics has reported Work In Process over the past 4 years, most recently at $6.3 million for Q4 2025.

  • Quarterly Work In Process rose 115.33% to $6.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.3 million through Dec 2025, up 115.33% year-over-year, with the annual reading at $6.3 million for FY2025, 115.33% up from the prior year.
  • Work In Process was $6.3 million for Q4 2025 at Gyre Therapeutics, up from $4.4 million in the prior quarter.
  • Over five years, Work In Process peaked at $6.3 million in Q4 2025 and troughed at $2.0 million in Q4 2023.
  • The 4-year median for Work In Process is $3.5 million (2024), against an average of $3.6 million.
  • Year-over-year, Work In Process crashed 45.54% in 2023 and then soared 115.33% in 2025.
  • A 4-year view of Work In Process shows it stood at $3.7 million in 2022, then crashed by 45.54% to $2.0 million in 2023, then surged by 46.67% to $2.9 million in 2024, then soared by 115.33% to $6.3 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Work In Process are $6.3 million (Q4 2025), $4.4 million (Q3 2025), and $4.2 million (Q2 2025).